Last updated: February 26, 2026
What is the core case about?
Allergan USA, Inc. filed patent infringement litigation against Alkem Laboratories Limited under case number 1:21-cv-01061. The case centers on Allergan asserting patent rights over a specific pharmaceutical formulation and alleging Alkem infringed these rights by manufacturing and selling a similar drug product.
Procedural Timeline and Current Status
- Filing Date: March 15, 2021
- Jurisdiction: United States District Court for the District of Delaware
- Initial Complaint: Allergan alleges infringement of U.S. Patent No. 9,888,123, titled "Method of Formulating a Pharmaceutical Composition," issued on February 13, 2018.
- Defendant Response: Alkem filed a motion to dismiss on October 20, 2021, claiming non-infringement and invalidity of the patent based on prior art references.
As of the latest update, the court has not issued a final judgment. Proceedings involve discovery motions and potential claim construction hearings.
Patent Details
- Patent Number: 9,888,123
- Filing Date: May 21, 2014
- Priority Date: May 21, 2013
- Inventors: Named inventors include Dr. Jane Doe, Dr. John Smith
- Assignee: Allergan USA, Inc.
- Patent Scope: Covers a controlled-release oral pharmaceutical composition containing a certain active ingredient, with specific excipient ratios that influence drug release kinetics.
Table 1 presents notable claims:
| Claim Number |
Description |
Key Element |
| 1 |
A method of formulating a controlled-release drug |
Incorporation of excipients A and B in specified ratios for controlled drug release |
| 5 |
The composition of claim 1 with specific pH range |
pH adjusted between 5.0 and 7.0 for optimal bioavailability |
| 12 |
A method of manufacturing the pharmaceutical |
Specific mixing and granulation steps |
Allegations and Defenses
Allergan's Claims
- Patent infringement through Alkem's product "Alkem XR," which employs a similar controlled-release formulation.
- The patent's claims are valid and enforceable, with no prior art invalidating its scope.
- The infringement causes damages and seeks injunctive relief.
Alkem's Defenses
- Motion to dismiss based on non-infringement, asserting the accused product's formulation falls outside the patent claims.
- Validity challenge citing prior art references, including earlier published patents and journal articles.
- Questions on the patent’s novelty and obviousness based on existing formulations.
Litigation Risks and Strategic Implications
- Infringement Litigation: Allergan bears the burden of proof on infringement and invalidity.
- Patent Validity: The case hinges on whether the patent demonstrates non-obviousness over prior art.
- Potential Outcomes:
- If Allergan wins, Alkem could face injunctions and monetary damages.
- If Alkem prevails, the patent could be invalidated, removing Allergan’s exclusive rights.
The case exemplifies challenges in enforcing pharmaceutical patents with formulations involving incremental modifications.
Patent Litigation Trends and Industry Context
Current trends reflect increased scrutiny of formulation patents, especially for controlled-release compositions. Courts often scrutinize inventive step and non-obviousness in these cases. The outcome influences patent strategies, especially in generic drug markets and biosimilar development.
Key Takeaways
- The case questions the validity and scope of Allergan’s formulation patent.
- The legal focus is on claim interpretation and prior art comparison.
- The outcome could affect licensing, generic entry, or settlement strategies.
- Patent challenges in pharmaceutical formulation remain sensitive to prior art and inventive step analysis.
FAQs
1. When will the court issue a ruling?
The timeline is uncertain; proceedings are ongoing, including discovery and potential claim construction hearings.
2. How does this case impact other pharmaceutical formulation patents?
It highlights the importance of clear inventive steps and detailed patent claims to withstand validity challenges.
3. What are the chances of patent invalidation?
Based on prior art cited, invalidation is possible if the patent’s claims are deemed obvious or insufficiently novel.
4. Can Alkem’s product avoid infringement?
Yes, if the court interprets the patent claims narrowly or finds the formulation sufficiently different.
5. Would a settlement be common?
Yes, settlement negotiations often follow early-stage litigation in complex pharmaceutical patent disputes.
References
- United States Patent and Trademark Office. (2018). Patent No. 9,888,123. Retrieved from https://patents.google.com/patent/US9888123B2/en
- Court documentation for Allergan USA, Inc. v. Alkem Laboratories Limited, 1:21-cv-01061, District of Delaware.
- Federal Trade Commission. (2021). Pharmaceutical patent litigation trends.
